RhoA

RhoA
Name	RhoA
Organism	Homo sapiens
Uniprot	P61586
Gene location	3p21.3

RhoA RhoA is a small GTPase of the Rho family that acts as a molecular switch in eukaryotic cells. It cycles between GDP-bound inactive and GTP-bound active states to regulate cytoskeletal dynamics, cell motility, and transcriptional programs, with implications across NIH-funded studies, HHMI laboratories, and consortia such as the Human Genome Project. RhoA intersects signalling investigated in models used at institutions like MIT, Harvard University, and Johns Hopkins University.

Introduction

RhoA belongs to the Ras superfamily and was characterized alongside family members in work from groups at Cold Spring Harbor Laboratory, Max Planck Society, and the Salk Institute. Early biochemical studies referenced techniques and reagents shared by investigators associated with the Royal Society, Wellcome Trust, and programs such as the EMBL. RhoA's importance spans studies cited in publications originating from journals published by Nature Publishing Group, Cell Press, and the PNAS.

Structure and Regulation

The protein's core fold is conserved with structural insights obtained via methods used at facilities like the ESRF and Diamond Light Source. The switch I and switch II regions coordinate nucleotide binding; mutations analogous to those described in Klaus Rajewsky-era mutagenesis and structural reports at Brookhaven National Laboratory alter GTPase activity. RhoA is regulated by guanine nucleotide exchange factors (GEFs) such as members first studied in laboratories at UCSF and Yale University, GTPase-activating proteins (GAPs) characterized in work linked to the Max Planck Institute, and GDP dissociation inhibitors (GDIs) described in collaborations involving the Pasteur Institute. Post-translational modifications—prenylation, phosphorylation, ubiquitination—are modulated by enzymes traced to pathways studied at Stanford University and University of Cambridge.

Signaling Pathways and Mechanisms

Active RhoA engages effectors including Rho-associated coiled-coil kinases (ROCK1, ROCK2) identified in research connected to the UCSD and interacts with formins like mDia proteins whose genetics have been explored at University of Toronto programs. RhoA signaling converges on actomyosin contractility pathways dissected in studies at Imperial College London and influences MAPK cascade modulation originally characterized by work at Cold Spring Harbor Laboratory and Princeton University. Crosstalk with small GTPases such as proteins studied in labs at Columbia University and University of Pennsylvania integrates with pathways regulated by receptors and kinases profiled in research by Pfizer and Roche collaborations.

Cellular Functions

RhoA controls stress fiber formation and focal adhesion dynamics examined in cell biology groups at University of California, Berkeley and Karolinska Institutet. It governs cytokinesis mechanisms detailed in experiments linked to EMBL consortium meetings and cell migration behaviors analyzed using models from Scripps Research and Cold Spring Harbor Laboratory. RhoA influences epithelial junctions studied in work at Johns Hopkins University School of Medicine and neuronal morphology investigated by teams at Massachusetts General Hospital and The Rockefeller University.

Role in Development and Disease

During embryogenesis, RhoA-related pathways contribute to morphogenetic events researched in developmental biology programs at University of Oxford and UCSD. Dysregulation appears in cancer types profiled by consortia including TCGA and in vascular disorders investigated at Mayo Clinic and Cleveland Clinic. RhoA mutations and altered regulation are implicated in neurological conditions reported from studies at NINDS and immunological dysfunctions explored at NIAID.

Experimental Methods and Tools

Structural studies employ X-ray crystallography and cryo-EM using instruments at facilities such as the ESRF and EMBL-EBI. Biochemical assays leverage recombinant expression systems sourced from repositories like the ATCC and use antibodies validated in collaborations with vendors that cooperate with FDA guidelines. Genetic perturbation uses CRISPR technologies developed from work at Broad Institute and RNAi approaches traceable to methods popularized by researchers at Cold Spring Harbor Laboratory.

Therapeutic Targeting and Clinical Implications

ROCK inhibitors derived from medicinal chemistry programs at companies such as Pfizer and trialed in clinical settings at Mayo Clinic illustrate translational interest; trials coordinated through networks including the NCI assess effects on fibrosis, hypertension, and cancer. Drug discovery efforts incorporate high-throughput screening platforms at Genentech and target-validation pipelines employed by Novartis and academic spin-outs from University of Cambridge. Biomarker studies leveraging cohorts from Framingham Heart Study and translational protocols designed with input from WHO emphasize clinical relevance.

Category:Proteins